Bringing this interview with Marla Black Morgan, MD, to a close, she looks to the future of research in both myasthenia ...

Myasthenia Gravis Foundation of America (MGFA™), the largest, leading patient advocacy organization in the United States solely dedicated to the myasthenia gravis (MG) community, announced the ...

MYASTHENIA gravis has frequently been described as a clinical entity. ... Laboratory examinations, including ... THYROID DISEASE AND MYASTHENIA GRAVIS, Thyroid Disease and Muscle Dysfunction ...

Concluding a recent interview with Jonathan Strober, MD, an investigator on the phase 2/3 Vibrance-MG study (NCT05265273) exploring pediatric use of nipocalimab for generalized myasthenia gravis ...

SOURCE Myasthenia Gravis Foundation of America, Inc. The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties.

Myasthenia gravis is a rare, chronic autoimmune disorder that causes serious muscle weakness. Frustrated Democrats try new response to Trump barrage: Flood the zone right back Lexi Thompson posts ...

Myasthenia gravis affects both men and women and occurs across all races and ethnicities. Its incidence and prevalence are higher in women under age 50 and in men ages 65 and older.

The FDA has approved Alexion's Soliris for use in patients with treatment resistant generalised Myasthenia gravis (gMG), making it the first new therapy for the condition in 60 years.

Cartesian Therapeutics enrolls first participant in Phase 3 trial of Descartes-08 for myasthenia gravis treatment. Quiver AI Summary. Cartesian Therapeutics, Inc. has announced the enrollment of ...

According to the data, after 24 weeks of treatment, 98.1% of patients in the Telitacicept group demonstrated a ≥ 3-point improvement in Myasthenia Gravis Activities of Daily Living ("MG-ADL ...

The NHS webpage on myasthenia gravis may be a good place to find out more. These organisations can give you advice and support: Myaware, 01332 290 219; Muscular Dystrophy UK, 0800 652 6352; You can ...

Evidence-based recommendations on efgartigimod (Vyvgart) for treating antibody-positive generalised myasthenia gravis in adults.. Last reviewed: 04 June 2025 Next review: This guidance will be ...